16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD); frontotemporal dementia; progressive supranuclear palsy (PSP) Patient sample and mouse studies suggest inhibiting LGMN-mediated cleavage of SRPK2 could help treat AD, frontotemporal dementia (FTD) and PSP. In brain tissue samples from...
18:06 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson's disease (PD) Patient sample and mouse studies suggest inhibiting LGMN could help treat PD. In postmortem brain tissue samples from PD and Lewy body dementia patients, levels of asparagine 103 α-synuclein, an LGMN-mediated...
08:00 , Jan 14, 2016 |  BC Innovations  |  Targets & Mechanisms

Moot point in AD

The longstanding β-amyloid vs. tau debate in Alzheimer's disease (AD) might turn out to be moot, according to findings from researchers at Emory University who identified a protease, AEP , that lies upstream of both...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Legumain (LGMN; AEP)

Neurology INDICATION: Alzheimer's disease (AD) In vitro, patient sample and mouse studies suggest inhibiting LGMN could help treat AD. Levels of LGMN were higher in postmortem brain tissue samples from AD patients than from healthy...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Legumain (LGMN; AEP); microtubule-associated protein-t (MAPT; tau; FTDP-17) In vitro, patient sample and mouse studies suggest inhibiting AEP could help treat AD....
07:00 , May 30, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Legumain (LGMN; AEP) Patient sample, tissue culture and in vitro studies suggest inhibiting AEP could help treat AD....
08:00 , Jan 10, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

This week in techniques Approach Summary Licensing status Publication and contact information Imaging Probe for functional imaging of legumain (LGMN) An activity-based fluorescent probe could be used to study the activity of LGMN, a protein...
07:00 , Apr 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ischemia Asparagine endopeptidase (AEP) In vitro and in vivo studies suggest that inhibiting AEP could be useful for treating neurodegeneration triggered...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

AtheroGenics board of directors update

AtheroGenics Inc. (AGIX), Atlanta, Ga.   Business: Cardiovascular, Autoimmune, Transplant   Appointed: Sam Barker, former president and CEO of Clearview Projects Inc.; and Margaret Grayson, EVP and general manager of AEP Networks  ...